search
Back to results

Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS) (BiC-8)

Primary Purpose

Acute Myocardial Infarction

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Discharge home
Sponsored by
Charite University, Berlin, Germany
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Acute Myocardial Infarction focused on measuring Copeptin, Troponin, Acute Coronary Syndrome, Rule-out of acute myocardial infarction, Emergency Medicine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Typical chest pain (with or without ECG-changes, but no ST-elevation)suggestive of unstable angina or non-ST-elevated myocardial infarction (NSTEMI)
  • Troponin negative at admission according to the current clinical practice Patient willing and able to give written informed consent

Exclusion Criteria:

  • Patients with ST-elevation myocardial infarction (STEMI)
  • Continuing chest pain or recurrent episodes of chest pain under therapy
  • High-risk patients with suspected ACS who need to be hospitalized for reasons independent of their initial troponin result
  • Patients who need to be hospitalized for other medical reasons
  • Patients in need of urgent life-saving interventions
  • Patients under 18 years of age
  • Patients with a life expectancy < 6 months
  • Patients with any condition that leads the treating physician to not consider the patient eligible for the trial

Sites / Locations

  • Wilhelminenspital Vienna
  • Kerckhoff-Klinik GmbH
  • Charité - Universitätsmedizin Berlin
  • Universitätsklinikum Hamburg-Eppendorf
  • Universitätsklinikum Heidelberg
  • University Hospital Basel

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Copeptin

Standard

Arm Description

Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software "Praxis-connect" i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room. Patients who test positive for Copeptin will be treated as by standard practise.

Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.

Outcomes

Primary Outcome Measures

Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.
Rate of MACE (all- cause death or survived sudden cardiac arrest, myocardial infarction, re-hospitalisation for acute coronary syndrome, acute unplanned PCI, coronary artery bypass grafting (CABG) and documented life-threatening arrhythmias (VF, VT, AV-block III)) within 30 days Copeptin vs. Control arm (non-inferiority).

Secondary Outcome Measures

Proportion of patients in whom coronary angiography (CA) is performed Copeptin vs. Control arm.
Efficacy endpoint Rate of Patients in whom CA is performed Rate of Patients with PCI after Index CA Rate of Patients with CABG after Index CA
Rate of ALL major adverse cardiac events (MACE)
Rate of ALL MACE at 90 days all- cause death or survived sudden cardiac arrest myocardial infarction re-hospitalisation for acute coronary syndrome acute unplanned PCI coronary artery bypass grafting (CABG) documented life-threatening arrhythmias (VF, VT, AV-block III)
Patient satisfaction regarding management within the ED/CPU
Patient satisfaction regarding management before discharge from ED/CPU
Length of hospital stay
Duration of hospital stay Length of stay at the Emergency Room Length of hospital stay in the CPU Length of stay in an intensive care unit (ICU) Total length of hospital stay in hours including time as an inpatient on other wards

Full Information

First Posted
October 25, 2011
Last Updated
June 4, 2013
Sponsor
Charite University, Berlin, Germany
Collaborators
Kerckhoff Klinik, Heidelberg University, Universitätsklinikum Hamburg-Eppendorf, Wilhelminenspital Vienna, University Hospital, Basel, Switzerland
search

1. Study Identification

Unique Protocol Identification Number
NCT01498731
Brief Title
Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS)
Acronym
BiC-8
Official Title
The Effect of Integrating the Biomarker Copeptin Into the Process of Managing Patients With Suspected ACS
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
June 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Charite University, Berlin, Germany
Collaborators
Kerckhoff Klinik, Heidelberg University, Universitätsklinikum Hamburg-Eppendorf, Wilhelminenspital Vienna, University Hospital, Basel, Switzerland

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Acute chest pain is commonly known to be the classic symptom of acute myocardial infarction. Of the many patients which visit the Emergency Department because of chest pain, less than half do actually suffer from an acute myocardial infarction or acute myocardial ischemia. In some patients the acute myocardial infarction can be diagnosed at admission, either because of typical changes in their ECG (STEMI, ST-elevation myocardial infarction)or because of increased levels of the laboratory value Troponin in their blood (NSTEMI, Non-ST-elevation myocardial infarction). Troponin is currently the most important marker to diagnose acute myocardial infarction. Unfortunately a lot of patients with suspected acute coronary syndrome do not show any ECG or Troponin changes. These patients pose a major problem in emergency medicine as they need to precautionally be admitted to a chest pain unit and to be started on medical treatment until a second Troponin test after 6-9 hours is available. In this study, we investigate the biomarker Copeptin. Copeptin has shown excellent results in diagnostic clinical trials assessing its use in various acute diseases. There are three important trials showing an excellent negative predictive value of Copeptin in combination with Troponin in patients with suspected acute coronary syndrome (Reichlin et al., JACC, 2009; Keller et al. JACC, 2010, Giannitsis et al. Clin Chem 2011). This trial compares two processes of managing patients with suspected acute coronary syndrome (ACS), the standard process according to current guidelines and the experimental process integrating copeptin as a rule-out marker for acute myocardial infarction into management decisions. Main Hypothesis: Patients with suspected ACS who test negative for Troponin and negative for Copeptin at their initial presentation to the ED can safely be discharged (interventional process). They will not experience more major cardiac adverse events than patients who were managed by standard practise (control process)within 30 days after admission. The Investigators want to test Copeptin in patients with suspected acute coronary syndrome in whom the ECG is unspecific and the initial Troponin test is negative. Further patient care will be based on the Copeptin result. Patients with a negative Copeptin will be discharged into the ambulant care of resident cardiologists.Copeptin positive patients will be managed according to standard guidelines for the management of patients with ACS.
Detailed Description
The management of patients with suspected Non-ST elevation acute coronary syndrome (NSTEACS) can be time-consuming and expensive. Often patients need to be hospitalized for precautionary medical treatment and serial Troponin testing until further decisions can be made. Copeptin, a 39 amino acid glycopeptide, is the C-terminal portion of Pro-Vasopressin. It is co-secreted from the posterior pituitary gland together with Vasopressin and mirrors the amount of Vasopressin in the circulation. Vasopressin is primarily known as Anti-Diuretic Hormone (ADH), which acts in the kidney to regulate the body's retention of water and in high concentration causes arterial vasoconstriction. Vasopressin is, as a central hormone, also a crucial part of the hypothalamo-pituitary-adrenal axis, which responds to severe, life-threatening "stress inputs"; its levels reflect the body's individual stress level.Vasopressin itself has a half-life of 5-10 minutes and is therefore difficult to measure in-vivo. Copeptin is secreted stoichiometrically with Vasopressin, it remains stable for days after blood withdrawal and can therefore easily be measured. Copeptin has been studied as a diagnostic and prognostic marker since 2006. In acute myocardial infarction Copeptin levels have been shown to increase early after the onset of symptoms (0-4 hours) and start decreasing after 4-5 hours. In acute myocardial infarction (AMI) Copeptin levels increase early after the onset of symptoms. In patients with suspected ACS Copeptin levels were significantly higher in patients with AMI than in patients with other diagnoses. Copeptin in conjunction with Troponin T was particularly useful as a rule-out marker of AMI. This is a randomized controlled diagnostic trial to quantify the benefit of integrating Copeptin into the management process of patients with NSTEACS and a negative baseline Troponin I test result in the Chest Pain Unit (CPU). Patient management will depend on Copeptin rather than serial Troponin results. Patients will be randomized in either a standard group (management according to current guidelines on managing patients with ACS, Copeptin will be tested, but result will not be revealed to treating personnel) or an interventional group (Copeptin testing, further management dependent on Copeptin result). In this interventional group, patients with a negative baseline Copeptin will be discharged into the ambulant care of co-operating resident cardiologists. Patients with a positive Copeptin result will be treated as by standard care (like patients in the control group). The investigators will assess the efficacy and safety of the new process as compared to the standard process. Secondary endpoints will assess patient satisfaction and length of hospital stay. This study design will not only assess the diagnostic use but also the clinical relevance of Copeptin testing in the ED/CPU. Consecutive N-STEACS patients of the Chest Pain Unit with a negative Troponin I at admission will be invited to participate. Troponin I is tested as part of the standard management of patients with suspected acute coronary syndrome on a point of care test device (POCT). Patients who give their written informed consent will then be randomized into one of two study arms (experimental and standard management) where further management depends on their Copeptin result at admission.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Myocardial Infarction
Keywords
Copeptin, Troponin, Acute Coronary Syndrome, Rule-out of acute myocardial infarction, Emergency Medicine

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
902 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Copeptin
Arm Type
Experimental
Arm Description
Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software "Praxis-connect" i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room. Patients who test positive for Copeptin will be treated as by standard practise.
Arm Title
Standard
Arm Type
No Intervention
Arm Description
Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.
Intervention Type
Behavioral
Intervention Name(s)
Discharge home
Intervention Description
Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
Primary Outcome Measure Information:
Title
Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.
Description
Rate of MACE (all- cause death or survived sudden cardiac arrest, myocardial infarction, re-hospitalisation for acute coronary syndrome, acute unplanned PCI, coronary artery bypass grafting (CABG) and documented life-threatening arrhythmias (VF, VT, AV-block III)) within 30 days Copeptin vs. Control arm (non-inferiority).
Time Frame
30 days after discharge
Secondary Outcome Measure Information:
Title
Proportion of patients in whom coronary angiography (CA) is performed Copeptin vs. Control arm.
Description
Efficacy endpoint Rate of Patients in whom CA is performed Rate of Patients with PCI after Index CA Rate of Patients with CABG after Index CA
Time Frame
within 30 days after discharge
Title
Rate of ALL major adverse cardiac events (MACE)
Description
Rate of ALL MACE at 90 days all- cause death or survived sudden cardiac arrest myocardial infarction re-hospitalisation for acute coronary syndrome acute unplanned PCI coronary artery bypass grafting (CABG) documented life-threatening arrhythmias (VF, VT, AV-block III)
Time Frame
90 days after discharge
Title
Patient satisfaction regarding management within the ED/CPU
Description
Patient satisfaction regarding management before discharge from ED/CPU
Time Frame
no specific time frame, before discharge
Title
Length of hospital stay
Description
Duration of hospital stay Length of stay at the Emergency Room Length of hospital stay in the CPU Length of stay in an intensive care unit (ICU) Total length of hospital stay in hours including time as an inpatient on other wards
Time Frame
within 30 days after discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Typical chest pain (with or without ECG-changes, but no ST-elevation)suggestive of unstable angina or non-ST-elevated myocardial infarction (NSTEMI) Troponin negative at admission according to the current clinical practice Patient willing and able to give written informed consent Exclusion Criteria: Patients with ST-elevation myocardial infarction (STEMI) Continuing chest pain or recurrent episodes of chest pain under therapy High-risk patients with suspected ACS who need to be hospitalized for reasons independent of their initial troponin result Patients who need to be hospitalized for other medical reasons Patients in need of urgent life-saving interventions Patients under 18 years of age Patients with a life expectancy < 6 months Patients with any condition that leads the treating physician to not consider the patient eligible for the trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin Möckel, MD, PhD
Organizational Affiliation
Charité - Universitätsmedizin Berlin, Berlin, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wilhelminenspital Vienna
City
Vienna
ZIP/Postal Code
1160
Country
Austria
Facility Name
Kerckhoff-Klinik GmbH
City
Bad Nauheim
ZIP/Postal Code
61231
Country
Germany
Facility Name
Charité - Universitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Facility Name
Universitätsklinikum Heidelberg
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
University Hospital Basel
City
Basel
ZIP/Postal Code
4031
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
17593313
Citation
Mockel M, Muller R, Vollert J, Muller C, Danne O, Gareis R, Stork T, Dietz R, Koenig W. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol. 2007 Sep;96(9):604-12. doi: 10.1007/s00392-007-0540-x. Epub 2007 Jun 27.
Results Reference
background
PubMed Identifier
17951287
Citation
Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007 Oct;28(20):2525-38. doi: 10.1093/eurheartj/ehm355. No abstract available.
Results Reference
background
PubMed Identifier
11294799
Citation
Newby LK, Storrow AB, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, Schreiber DH, Tuttle RH, McNulty SE, Ohman EM. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation. 2001 Apr 10;103(14):1832-7. doi: 10.1161/01.cir.103.14.1832.
Results Reference
background
PubMed Identifier
10770981
Citation
Pope JH, Aufderheide TP, Ruthazer R, Woolard RH, Feldman JA, Beshansky JR, Griffith JL, Selker HP. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. 2000 Apr 20;342(16):1163-70. doi: 10.1056/NEJM200004203421603.
Results Reference
background
PubMed Identifier
15089973
Citation
Itoi K, Jiang YQ, Iwasaki Y, Watson SJ. Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol. 2004 Apr;16(4):348-55. doi: 10.1111/j.0953-8194.2004.01172.x.
Results Reference
background
PubMed Identifier
18580851
Citation
Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008 Jun;29(3):341-6.
Results Reference
background
PubMed Identifier
17420344
Citation
Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007 Apr 24;115(16):2103-10. doi: 10.1161/CIRCULATIONAHA.106.685503. Epub 2007 Apr 9.
Results Reference
background
PubMed Identifier
19555842
Citation
Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009 Jun 30;54(1):60-8. doi: 10.1016/j.jacc.2009.01.076.
Results Reference
background
PubMed Identifier
19346228
Citation
Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K; OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009 May;30(10):1187-94. doi: 10.1093/eurheartj/ehp098. Epub 2009 Apr 3.
Results Reference
background
PubMed Identifier
20447532
Citation
Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF, Blankenberg S. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010 May 11;55(19):2096-106. doi: 10.1016/j.jacc.2010.01.029.
Results Reference
background
PubMed Identifier
16269513
Citation
Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006 Jan;52(1):112-9. doi: 10.1373/clinchem.2005.060038. Epub 2005 Nov 3.
Results Reference
background
PubMed Identifier
21807867
Citation
Giannitsis E, Kehayova T, Vafaie M, Katus HA. Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarction. Clin Chem. 2011 Oct;57(10):1452-5. doi: 10.1373/clinchem.2010.161265. Epub 2011 Aug 1.
Results Reference
background
PubMed Identifier
35053326
Citation
Giannitsis E, Garfias-Veitl T, Slagman A, Searle J, Muller C, Blankenberg S, von Haehling S, Katus HA, Hamm CW, Huber K, Vollert JO, Mockel M. Biomarkers-in-Cardiology 8 RE-VISITED-Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome-A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial. Cells. 2022 Jan 8;11(2):211. doi: 10.3390/cells11020211.
Results Reference
derived
PubMed Identifier
30138394
Citation
Reinhold T, Giannitsis E, Mockel M, Frankenstein L, Vafaie M, Vollert JO, Slagman A. Cost analysis of early discharge using combined copeptin/cardiac troponin testing versus serial cardiac troponin testing in patients with suspected acute coronary syndrome. PLoS One. 2018 Aug 23;13(8):e0202133. doi: 10.1371/journal.pone.0202133. eCollection 2018.
Results Reference
derived

Learn more about this trial

Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS)

We'll reach out to this number within 24 hrs